Members Wealth LLC Sells 451 Shares of Cencora, Inc. (NYSE:COR)

Members Wealth LLC lessened its holdings in Cencora, Inc. (NYSE:COR) by 31.5% during the first quarter, HoldingsChannel.com reports. The firm owned 979 shares of the company’s stock after selling 451 shares during the period. Members Wealth LLC’s holdings in Cencora were worth $272,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC raised its position in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after acquiring an additional 46 shares in the last quarter. Banque Transatlantique SA bought a new stake in Cencora during the fourth quarter worth $29,000. SBI Securities Co. Ltd. bought a new stake in Cencora during the fourth quarter worth $30,000. Kentucky Trust Co bought a new stake in Cencora during the fourth quarter worth $33,000. Finally, WASHINGTON TRUST Co raised its position in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after acquiring an additional 46 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on COR shares. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Robert W. Baird upped their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Bank of America upped their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. Citigroup upped their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Finally, Wells Fargo & Company upgraded shares of Cencora from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $306.91.

Cencora Price Performance

NYSE:COR opened at $286.34 on Thursday. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. The company has a market cap of $55.50 billion, a P/E ratio of 40.73, a P/E/G ratio of 1.31 and a beta of 0.58. The firm’s fifty day moving average price is $286.42 and its two-hundred day moving average price is $260.98. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the prior year, the company posted $3.80 earnings per share. Cencora’s revenue was up 10.3% compared to the same quarter last year. Equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Cencora’s dividend payout ratio (DPR) is presently 25.52%.

Insider Activity at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the sale, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the sale, the chairman now owns 315,913 shares in the company, valued at $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,253 shares of company stock worth $10,582,297. Corporate insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.